Relationship of Hepatitis B or C Virus Prevalences, Risk Factors, and Outcomes in Renal Transplant Recipients: Analysis of German Data

Kliem, Volker; Burg, M.P.M. van der; Haller, H.; Suwelack, Barbara; Abendroth, D.; Fritsche, Lutz; Fornara, Paolo; Pietruck, Frank; Frei, Ulrich; Donauer, Johannes; Lison, Arno E.; Michel, U.

doi:10.1016/j.transproceed.2008.03.031

Cited by 32 publications

(24 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding supports the results of other studies revealing that transaminase elevation in anti-HCV-positive RTx patients does not affect liverrelated patient survival (25,26). Similarly, even though viral replication continued in 33.7% of patients, patient and graft survivals were not associated with elevated ALT level or type of immunosuppression.…”

Section: Parameters Hcv (+) (N=100) Hcv (-) (N=1711) P Valuesupporting

confidence: 92%

“…Some studies suggest that HCV infection adversely affects patient and graft survivals and that this is related to cardiovascular disease, post-transplant diabetes mellitus and infection/sepsis (10,(23)(24)(25). In another group of studies, there was no difference between the groups in terms of patient/graft…”

Section: Parameters Hcv (+) (N=100) Hcv (-) (N=1711) P Valuementioning

confidence: 99%

See 1 more Smart Citation

The impact of hepatitis C virus infection on long-term outcome in renal transplant patients

Ruhı

Süleymanlar²,

Koçak³

et al. 2011

Turk J Gastroenterol

View full text Add to dashboard Cite

Section: Parameters Hcv (+) (N=100) Hcv (-) (N=1711) P Valuesupporting

confidence: 92%

Section: Parameters Hcv (+) (N=100) Hcv (-) (N=1711) P Valuementioning

confidence: 99%

The impact of hepatitis C virus infection on long-term outcome in renal transplant patients

Ruhı

Süleymanlar²,

Koçak³

et al. 2011

Turk J Gastroenterol

View full text Add to dashboard Cite

“…Epidemiology Hepatitis B virus Hepatotropic viral infections, including HBV, are more frequent in renal transplant recipients and dialysis patients than in the general population and have a significant impact on the survival of these patients [2][3][4][5]. Viral hepatitis is reported in about 15-20% of heart transplant recipients [6][7][8][9].…”

Section: What Is Already Knownmentioning

confidence: 99%

“…HCV infection is more frequent in renal transplant recipients and dialysis patients than in the general population and has a significant impact on the survival of these patients [1,4,5,[12][13][14][15]. HCV infection is frequent in hemodialyzed patients, with a prevalence ranging between 10% and 65% according to the geographical zone.…”

Section: Hepatitis C Virusmentioning

confidence: 99%

VIRAL hepatitis in solid organ transplantation other than liver

Vallet-Pichard¹,

Fontaine²,

Mallet³

et al. 2011

Journal of Hepatology

View full text Add to dashboard Cite

Transplantation is the best treatment for end-stage organ failure. Hepatitis virus infections, mainly hepatitis B virus (HBV) and hepatitis C virus (HCV) infections still constitute a major problem because they are common in allograft recipients and are a significant cause of morbidity and mortality after transplantation. Recently, hepatitis E virus infection has been added as an emergent cause of chronic hepatitis in organ transplantation. The prevalence of HBV and HCV infections has markedly decreased in patients who are candidates for transplantation since the introduction of screening, hygiene and prevention measures, including systematic screening of blood and organ donations, use of erythropoietin, compliance with universal hygiene rules, segregation of HBV-infected patients from non-infected patients and systematic vaccination against HBV. A liver biopsy is preferable to non-invasive biochemical and/or morphological tests of fibrosis to evaluate liver fibrosis before and even after transplantation. Treatment with entecavir or tenofovir is indicated in HBV-infected dialyzed patients who have moderate or severe disease (≥A2 or F2 on the Metavir scale) in preparation for renal transplantation. Due to the risks of severe reactivation, fibrosing cholestatic hepatitis or histological deterioration after transplantation, systematic use of nucleoside or nucleotide analogues shortly before or at the time of transplantation is recommended (tenofovir or entecavir are preferable to lamivudine) in all patients, whatever the baseline histological evaluation. In HCV-infected dialyzed patients who are not candidates for renal transplantation, the indication for antiviral therapy is limited to significant fibrosis (fibrosis ≥2 on the Metavir scale). Treatment must be proposed to all candidates for renal transplantation, whatever their baseline histopathology, and interferon-α should be used as monotherapy. After transplantation, interferon-α is contraindicated but may be used in patients for whom the benefits of antiviral treatment clearly outweigh the risks, especially that of allograft rejection. All cirrhotic patients, notably after solid organ transplantation, should be screened for hepatocellular carcinoma. Sustained suppression of necro-inflammation may result in regression of cirrhosis, which in turn may lead to decreased disease-related morbidity and improved survival. Finally, due to the high mortality after renal transplantation, active (namely without sustained viral suppression) cirrhosis should be considered a contraindication to kidney transplantation, but an indication to combined liver-kidney transplantation; on the contrary, inactive (namely with sustained viral suppression) compensated cirrhosis may permit renal transplantation alone. Organ transplantations other than kidney (cardiac or pulmonary transplantations) involve the same diagnosis and therapeutic issues.

show abstract

“…Hepatitis B-Impfung · Dauer des Schutzes · Impfempfehlung · Ständige Impfkommission (STIKO) · Deutschland F Indication group 1: Persons at risk of severe hepatitis B due to existing or expected immunodeficiency or -suppression or due to other preexisting diseases.Examples: HIV-positive individuals, hepatitis C-positive persons [6,7], patients on hemodialysis [8,9,10]. F Indication group 2: Persons at increased risk of non-occupational exposure.Examples: Persons living together with HBsAg carriers [11,12,13], persons at high risk of acquiring hepatitis B by sexual contact [11,14,15], people who inject drugs [14,16,17], prison inmates [18,19,20], psychiatric inpatients [21,22].…”

Section: Schlüsselwörtermentioning

confidence: 99%

Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany

Harder

Remschmidt

Falkenhorst

et al. 2013

Bundesgesundheitsbl.

View full text Add to dashboard Cite

Relationship of Hepatitis B or C Virus Prevalences, Risk Factors, and Outcomes in Renal Transplant Recipients: Analysis of German Data

Cited by 32 publications

References 38 publications

The impact of hepatitis C virus infection on long-term outcome in renal transplant patients

The impact of hepatitis C virus infection on long-term outcome in renal transplant patients

VIRAL hepatitis in solid organ transplantation other than liver

Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany

Contact Info

Product

Resources

About